Keywords
Risk assessment
Control
Submitted : 2024-01-26
Accepted : 2024-02-10
Published : 2024-02-25
Abstract
The risk assessment and control of medical investment, merger, and acquisition are crucial topics within the medical industry, encompassing various aspects of investment, merger, and acquisition within this sector. The process primarily targets the unique nature and associated risks of the medical industry, focusing on effective risk management and control strategies to facilitate the smooth progression of investment, merger, and acquisition activities.
References
Hong L, Chen S, Han F, 2015, Overseas Merger and Acquisitions, Organizational Control, and Investment Mode Selection –Based on Empirical Evidence from China. Management World, 2015(10): 40–53.
Zheng B, Shi H, 2020, A Research on the Decision-Making Method for Enterprise Merger and Acquisitions Considering the Synergetic Effect – Exemplified by 63 Biological and New Pharmaceutical Enterprises in Fuzhou. Southeast Academic Research, 2020(2): 207–216.
Chen S-H, Zhang Z, Song B-S, 2020, What Kind of Failure is the Mother of Success? Evidence from the Impact of M&A Failure on Subsequent M&A Performance. Business Management Journal, 2020(4): 20–36.
Zhao Y, Qiao P, 2018, Do Motives for Cross-Border M&As Affect Ownership Choice? The Moderating Role of Firm Profitability. Foreign Economies and Management, 40(2): 51–67 + 137.
Jia P, 2017, The Development Trends and Situation Assessment of Chinese Enterprises Participating in Cross-Border Merger and Acquisitions – Based on the Practice of China’s “Going Global” Strategy. Practice in Foreign Economic Relations and Trade, 2017(7): 77–80.
Li Q, 2023, Financial Risk Control Strategies in Pharmaceutical Company Merger and Acquisitions. Economic and Social Development, 2023(2): 49–52.
Chang R, 2020, Risk Assessment and Prevention Research on Target Company Valuation in Corporate Merger and Acquisitions – A Case Study of QS Company’s Acquisition of LW Company. Contemporary Accounting, 2020(11): 151–152.
Kong N, 2022, Research on Financial Risk of Continuous Merger and Acquisitions of Pharmaceutical Enterprises Under Related Diversification Strategy – Take Zhongsheng Pharmaceutical as an Example, thesis, Northern University for Nationalities.
Dai D, 2020, Research on Financial Risk of M&A of Pharmaceutical Enterprises – Take China Resources Sanjiu Acquisition of Zhongyi Pharmaceutical as an Example, thesis, Chongqing University of Technology.
Chen S, 2019, Research on the Financial Risk and Control Strategy of the Merger and Acquisition of Pharmaceutical Enterprises. Finance, 2019(27): 97–98.
Wang X, 2021, A Case Study on the Financial Risk and Management Control of Merger and Acquisitions of Pharmaceutical Enterprises. National Circulation Economy, 2021(5): 55–57.
Li Z, 2019, Exploration of the Financial Risk Management Strategy of Merger and Acquisitions of Pharmaceutical Enterprises. Modern Commerce and Trade Industry, 2019(16): 115–116.
Li J, 2018, On the Financial Risk and Control of Merger and Acquisitions of Pharmaceutical Enterprises. Knowledge Economy, 2018(8): 85–86.
Xu F, 2020, Research on Financial Risk Analysis and Prevention of SDJC Pharmaceutical Company – Take PG Drug Source as an Example, thesis, Shandong University of Technology.
Liao L, 2020, Study on the Synergistic Effect of Pharmaceutical Companies Acquiring Hospitals – Take Jimin Pharmaceutical as an Example, thesis, Jinan University.